Bristol Myers Squibb Bolsters Neuroscience Portfolio with Karuna Therapeutics Acquisition
Princeton, N.J. & Boston - In a strategic move to expand its neuroscience portfolio, pharmaceutical giant Bristol Myers Squibb (BMY) has announced its acquisition of Karuna Therapeutics, Inc. (KRTX), a clinical-stage biopharmaceutical company focused on developing novel treatments for neuropsychiatric disorders. The merger agreement, involving a cash deal worth $14.0 billion ($12.7 billion net of estimated cash acquired), has been unanimously approved by the boards of both companies.
The acquisition comes as Bristol Myers Squibb recognizes the growing need for innovative therapies to address the unmet medical needs of patients suffering from debilitating neurological and psychiatric conditions. By incorporating Karuna Therapeutics’ groundbreaking research and development capabilities into its own initiatives, Bristol Myers Squibb aims to strengthen its position in the neuroscience sector and deliver meaningful advancements to patients worldwide.
Karuna Therapeutics is at the forefront of developing therapies targeting muscarinic cholinergic receptors in the brain, a promising area of investigation for neuropsychiatric disorders such as schizophrenia and Alzheimer’s disease. With its proprietary platform and deep understanding of the underlying neurobiology, Karuna Therapeutics has been able to identify and advance several potential therapeutic candidates into late-stage clinical trials. The acquisition by Bristol Myers Squibb provides an opportunity to harness this groundbreaking research and leverage the significant resources and global presence of the pharmaceutical giant to accelerate the development and commercialization process.
Dr. Giovanni Caforio, Chairman and Chief Executive Officer of Bristol Myers Squibb, expressed his enthusiasm for the partnership, stating, We are pleased to bring Karuna’s groundbreaking research and development capabilities into Bristol Myers Squibb to reinforce our leading position in neuroscience. Through this acquisition, we are expanding our portfolio with innovative treatments and enhancing our ability to deliver transformational medicines to patients with neuropsychiatric disorders.
Karuna Therapeutics will benefit from Bristol Myers Squibb’s extensive clinical development, regulatory, and commercialization expertise, which will enable the accelerated advancement of its pipeline candidates. The acquisition will also foster collaboration and knowledge-sharing between both organizations, creating a synergy of resources that will drive scientific innovation and the pursuit of groundbreaking therapies for neurological and psychiatric disorders.
The completion of the transaction is subject to customary closing conditions, including the approval of shareholders of Karuna Therapeutics and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Comments